Ablative treatments for locally advanced pancreatic cancer: the CROSSFIRE trial: Authors' reply
- PMID: 38971162
- DOI: 10.1016/S2468-1253(24)00162-6
Ablative treatments for locally advanced pancreatic cancer: the CROSSFIRE trial: Authors' reply
Conflict of interest statement
MRM, HJS, BG, and FEFT received research funding from the Adessium Foundation, AngioDynamics, and Idera Pharmaceuticals for the conduct of the CROSSFIRE trial and the PANFIRE 3 trial. MRM and HJS received research funding from AngioDynamics and Immunophotonics for the conduct of the INJECTABLE-II trial. AMEB received research funding and speakers fees from ViewRay. MRM received research funding from Johnson & Johnson and Medtronic. MRM, HJS, BG, and FEFT received travel support from AngioDynamics. MRM and HJS received consulting fees from AngioDynamics, and MRM received consulting fees from Medtronic.
Comment on
-
Ablative treatments for locally advanced pancreatic cancer: the CROSSFIRE trial.Lancet Gastroenterol Hepatol. 2024 Aug;9(8):687. doi: 10.1016/S2468-1253(24)00130-4. Lancet Gastroenterol Hepatol. 2024. PMID: 38971163 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
